Tanja Langsenlehner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3345340/publications.pdf

Version: 2024-02-01

516710 610901 33 598 16 24 citations g-index h-index papers 33 33 33 1095 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Can Pre-Treatment Inflammatory Parameters Predict the Probability of Sphincter-Preserving Surgery in Patients with Locally Advanced Low-Lying Rectal Cancer?. Diagnostics, 2021, 11, 946.	2.6	O
2	The $\hat{l}\pm 2$ -isoform of the Na ⁺ /K ⁺ -ATPase protects against pathological remodeling and \hat{l}^2 -adrenergic desensitization after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H650-H662.	3.2	12
3	Reply to Blaustein et al American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H119-H1120.	3.2	O
4	The Elevated Pre-Treatment C-Reactive Protein Predicts Poor Prognosis in Patients with Locally Advanced Rectal Cancer Treated with Neo-Adjuvant Radiochemotherapy. Diagnostics, 2020, 10, 780.	2.6	5
5	The decreased mean platelet volume is associated with poor prognosis in patients with oropharyngeal cancer treated with radiotherapy. Radiation Oncology, 2020, 15, 259.	2.7	10
6	The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer. Diagnostics, 2020, 10, 973.	2.6	26
7	Haptoglobin polymorphism and prostate cancer mortality. Scientific Reports, 2020, 10, 13117.	3.3	5
8	The Erythropoetin rs1617640 Gene Polymorphism Associates with Hemoglobin Levels, Hematocrit and Red Blood Cell Count in Patients with Peripheral Arterial Disease. Genes, 2020, 11, 1305.	2.4	3
9	Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer. Radiation Oncology, 2020, 15, 99.	2.7	3
10	The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy. Cancers, 2020, 12, 626.	3.7	11
11	Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients. In Vivo, 2020, 34, 3631-3638.	1.3	O
12	In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. Cancers, 2019, 11, 933.	3.7	18
13	Relative telomere length and prostate cancer mortality. Prostate Cancer and Prostatic Diseases, 2018, 21, 579-583.	3.9	19
14	Catch and Release: rare cell analysis from a functionalised medical wire. Scientific Reports, 2017, 7, 43424.	3.3	17
15	BCL2Âgenotypes and prostate cancer survival. Strahlentherapie Und Onkologie, 2017, 193, 466-471.	2.0	22
16	TRPC4 \hat{l}_{\pm} and TRPC4 \hat{l}^{2} Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation. PLoS ONE, 2016, 11, e0168446.	2.5	9
17	Rebuttal to "Causal effect of vitamin D on prostate cancer using Mendelian randomization approach― World Journal of Urology, 2016, 34, 615-615.	2.2	O
18	Vitamin D and prostate cancer prognosis: a Mendelian randomization study. World Journal of Urology, 2016, 34, 607-611.	2.2	17

#	Article	IF	CITATIONS
19	The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumor Biology, 2016, 37, 361-368.	1.8	39
20	Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World Journal of Urology, 2015, 33, 1661-1667.	2.2	43
21	Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 201.e9-201.e16.	1.6	25
22	The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. European Journal of Cancer, 2015, 51, 610-619.	2.8	49
23	An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients. Breast, 2015, 24, 667-672.	2.2	31
24	The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients. World Journal of Urology, 2015, 33, 1467-1473.	2.2	27
25	Low spinophilin expression enhances aggressive biological behavior of breast cancer. Oncotarget, 2015, 6, 11191-11202.	1.8	10
26	The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer. Anticancer Research, 2012, 32, 3473-8.	1.1	3
27	Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiotherapy and Oncology, 2011, 98, 387-393.	0.6	46
28	Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlentherapie Und Onkologie, 2011, 187, 784-791.	2.0	14
29	Treatment Results of Radiation Therapy for Muscle-Invasive Bladder Cancer. Strahlentherapie Und Onkologie, 2010, 186, 203-209.	2.0	16
30	The Role of Radiation Therapy after Incomplete Resection of Penile Cancer. Strahlentherapie Und Onkologie, 2008, 184, 359-363.	2.0	17
31	The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate, 2008, 68, 264-268.	2.3	24
32	Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. European Journal of Cancer, 2008, 44, 1572-1576.	2.8	39
33	Long-Term Follow-up of Patients with Pituitary Macroadenomas after Postoperative Radiation Therapy. Strahlentherapie Und Onkologie, 2007, 183, 241-247.	2.0	38